ReviewCureus2025
Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endometrial cancer molecular classification: research advances and clinical application.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With an increasing incidence, endometrial cancer (EC) is the most prevalent gynecologic cancer in developed countries. Although histological classification has been used traditionally, its usage in forecasting clinical behavior was less effective. A molecular classification of EC has been introduced by the Cancer Genome Atlas (TCGA), which has separated it into four subgroups: p53-abnormal (p53abn), mismatch repair deficiency (MMRd), polymerase epsilon (POLE)-mutated (POLEmut), and no specific molecular profile (NSMP). The prognostic value of this molecular subtyping is superior. This narrative review analyzes the clinicopathological features of MMRd tumors, highlighting their intermediate prognosis relative to other molecular subtypes, while also noting associations with high-grade, lymphovascular space invasion, and lymph node metastasis. For this purpose, relevant studies were retrieved from PubMed, Scopus, and Web of Science up to 2025, focusing on clinicopathological correlations and treatment outcomes. Furthermore, we analyze the important therapeutic implications of MMR status. About 25%-30% of cases are classified as MMRd EC and are associated with an intermediate prognosis. The increased mutational burden in MMRd tumors enhances their susceptibility to immune checkpoint inhibitors such as pembrolizumab and dostarlimab, which have demonstrated considerable efficacy and altered the treatment approach for patients with advanced or recurrent MMRd EC. This review highlights the significance of MMR testing in risk stratification, prognosis, and planning of personalized treatment, ultimately improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.